BLOOMFIELD, Conn., Feb. 20,
2024 /PRNewswire/ -- The Cigna Group (NYSE: CI)
announced today the pricing terms of its previously announced
offers to purchase for cash (1) any and all of The Cigna Group's
(the "Company") 3.50% Senior Notes due 2024 and
Evernorth Health, Inc.'s ("Evernorth") 3.50% Senior
Notes due 2024 (collectively, the "Any and All
Notes," and such tender offer, the "Any and All
Tender Offer") and (2) up to $1,550,000,000 aggregate principal amount (the
"Maximum Tender Offer Amount") of the Company's
4.125% Senior Notes due 2025, the Company's 4.500% Senior Notes due
2026, Evernorth's 4.500% Senior Notes due 2026, the Company's
1.250% Senior Notes due 2026, the Company's 3.050% Senior Notes due
2027, Cigna Holding Company's 3.050% Senior Notes due 2027 and the
Company's 2.400% Senior Notes due 2030 (collectively, the
"Maximum Tender Offer Notes," and such tender offer,
the "Maximum Tender Offer"), in each case, validly
tendered and accepted by the Company, upon the terms and subject to
the conditions set forth in the Offer to Purchase dated
February 5, 2024 and as amended by
the press release dated the date hereof announcing the early
results of the Tender Offers (as defined below) and the upsize of
the Maximum Tender Offer (the "Offer to Purchase").
The Any and All Notes and the Maximum Tender Offer Notes are
referred to collectively as the "Securities" and the
Any and All Tender Offer and the Maximum Tender Offer are referred
to collectively as the "Tender Offers."
The "Total Consideration" payable per $1,000 principal amount of each series of
Securities validly tendered and accepted for purchase was
determined by the Dealer Managers (as named below) based on a
spread over a reference U.S. Treasury Security, as set forth in the
tables below, in accordance with standard market practice as of
10:00 a.m., New York City time, on February 20, 2024 (the "Price Determination
Time") and, as set forth in the tables below, includes an
Early Tender Payment of $30. As
previously announced, the Company does not expect to accept any of
the Company's 3.050% Senior Notes due 2027 or Cigna Holding
Company's 3.050% Senior Notes due 2027. Any and All Notes validly
tendered and not validly withdrawn will be accepted as set forth in
the Offer to Purchase until the Expiration Date (as defined
below).
The following table summarizes the material pricing terms for
the Tender Offers:
Any and All Tender Offer
Title of
Security
|
CUSIP
Numbers
|
Fixed
Spread
(bps)
|
Reference
U.S. Treasury
Security
|
Reference
Yield
|
Total
Consideration(a)(b)
|
The Cigna
Group's 3.50%
Senior Notes due
2024
|
125523BX7;
125523BW9;
U1716AAT4
|
20
|
0.250% U.S.
Treasury
Notes
due June 15,
2024
|
5.406 %
|
$993.39
|
Evernorth Health,
Inc.'s 3.50%
Senior Notes due
2024
|
30219GAK4
|
20
|
0.250% U.S.
Treasury
Notes
due June 15,
2024
|
5.406 %
|
$993.39
|
|
|
|
|
|
|
(a)
|
Per $1,000 principal
amount.
|
(b)
|
Total Consideration is
based on the Fixed Spread for the applicable series of Securities
to the yield of the Reference U.S. Treasury Security for that
series as of 10:00 a.m., New York City time, on February 20, 2024.
The Total Consideration excludes accrued and unpaid interest on the
Securities
accepted for purchase and includes an Early Tender Payment of
$30.
|
Maximum Tender Offer
Title of
Security
|
CUSIP
Numbers
|
Acceptance
Priority
Level(a)
|
Fixed
Spread
(bps)
|
Reference
U.S.
Treasury
Security
|
Reference
Yield
|
Total
Consideration(b)(c)
|
The Cigna
Group's 4.125%
Senior Notes due
2025
|
125523AG5;
40573LAQ9;
U4058LAH6
|
1
|
45
|
4.250% U.S.
Treasury
Notes
due January
31, 2026
|
4.584 %
|
$985.05
|
The Cigna
Group's 4.500%
Senior Notes due
2026
|
125523BZ2;
125523BY5;
U1716AAU1
|
2
|
45
|
4.250% U.S.
Treasury
Notes
due January
31, 2026
|
4.584 %
|
$989.92
|
Evernorth Health,
Inc.'s 4.500%
Senior Notes due
2026
|
30219GAM0
|
2
|
45
|
4.250% U.S.
Treasury
Notes
due January
31, 2026
|
4.584 %
|
$989.92
|
The Cigna
Group's 1.250%
Senior Notes due
2026
|
125523CP3
|
3
|
45
|
4.250% U.S.
Treasury
Notes
due January
31, 2026
|
4.584 %
|
$926.69
|
The Cigna
Group's 2.400%
Senior Notes due
2030
|
125523CL2
|
5
|
75
|
4.000% U.S.
Treasury
Notes
due January
31, 2029
|
4.231 %
|
$866.32
|
|
|
|
|
|
|
|
(a)
|
We will accept the
Maximum Tender Offer Notes in the order of their respective
Acceptance Priority Level specified in the table above (each,
an
"Acceptance Priority Level," with "1" being the highest Acceptance
Priority Level and "5" being the lowest Acceptance Priority Level),
upon the terms
and subject to the conditions set forth in the Offer to Purchase,
including the Maximum Tender Offer Amount, the 2025-2026 Tender
Sub-Cap, the
2026-2027 Tender Sub-Cap and the 2030 Tender Sub-Cap (each as
defined in the Offer to Purchase and, as applicable, as amended in
the
Company's previously announced press release dated the date
hereof).
|
(b)
|
Per $1,000 principal
amount.
|
(c)
|
Total Consideration is
based on the Fixed Spread for the applicable series of Securities
to the yield of the Reference U.S. Treasury Security for that
series as of 10:00 a.m., New York City time, on February 20, 2024.
The Total Consideration excludes accrued and unpaid interest on the
Securities
accepted for purchase and includes an Early Tender Payment of
$30.
|
As previously announced, it is anticipated that payment for the
Securities that were validly tendered and accepted for purchase as
of 5:00 p.m., New York City time, on February 16, 2024 (the "Early Tender
Date") will be made on February
22, 2024.
The Tender Offers will expire at 5:00
p.m., New York City Time, on March 5,
2024 (such time and date, as the same may be extended, the
"Expiration Date"). As previously announced, because
the Maximum Tender Offer has been fully subscribed as of the Early
Tender Date, the Company does not expect to accept for purchase any
Maximum Tender Offer Notes tendered by holders after the Early
Tender Date. Any and All Notes validly tendered and not validly
withdrawn will be accepted as set forth in the Offer to Purchase
until the Expiration Date.
Additional Information
J.P. Morgan Securities LLC, Deutsche Bank Securities Inc.,
Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC are the
Dealer Managers for the Tender Offers. D.F. King & Co., Inc.
has been appointed as the tender agent and information agent for
the Tender Offers.
Persons with questions regarding the Tender Offers should
contact J.P. Morgan Securities LLC at (212) 834-3554 (collect) or
(866) 834-4666 (toll-free), Deutsche Bank Securities Inc. at (212)
250-2955 (collect) or (866) 627-0391 (toll-free), Goldman Sachs
& Co. LLC at (212) 902-5962 (collect) or (800) 828-3182
(toll-free) and Wells Fargo Securities, LLC at (704) 410-4759
(collect) or (866) 309-6316 (toll-free). The Offer to Purchase will
be distributed to holders of Securities promptly. Holders who would
like additional copies of the Offer to Purchase may contact the
information agent, D.F. King & Co., Inc. at
www.dfking.com/cigna, by calling toll-free at (888) 567-1626 (banks
and brokers may call collect at (212) 269-5550) or by email at
cigna@dfking.com.
This press release is not an offer to sell or a solicitation of
an offer to buy any security. The Tender Offers are being made
solely pursuant to the Offer to Purchase.
The Tender Offers do not constitute, and the Offer to Purchase
may not be used in connection with, an offer or solicitation by
anyone in any jurisdiction in which such offer or solicitation is
not permitted by law or in which the person making such offer or
solicitation is not qualified to do so or to any person to whom it
is unlawful to make such offer or solicitation.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company
committed to creating a better future built on the vitality of
every individual and every community. We relentlessly challenge
ourselves to partner and innovate solutions for better health. The
Cigna Group includes products and services marketed under Evernorth
Health Services, Cigna Healthcare, or its subsidiaries. The Cigna
Group maintains sales capabilities in more than 30 countries and
jurisdictions, and has approximately 165 million customer
relationships around the world. Learn more at
www.thecignagroup.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
This press release, and oral statements made in connection with
this release, may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are based on The Cigna Group's current
expectations and projections about future trends, events and
uncertainties. These statements are not historical facts.
Forward-looking statements may include, among others, statements
concerning successful completion of the Tender Offers and other
statements regarding our future beliefs, expectations, plans,
intentions, financial condition or performance. You may identify
forward-looking statements by the use of words such as "believe,"
"expect," "project," "plan," "intend," "anticipate," "estimate,"
"predict," "potential," "may," "should," "will" or other words or
expressions of similar meaning, although not all forward-looking
statements contain such terms.
Forward-looking statements are subject to risks and
uncertainties, both known and unknown, that could cause actual
results to differ materially from those expressed or implied in
forward-looking statements. The discussions in our Annual Report on
Form 10-K for the year ended December 31,
2022, including the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections therein, as such discussions may be updated
from time to time in our periodic filings with the Securities and
Exchange Commission incorporated by reference in the Offer to
Purchase, include both expanded discussion of these factors and
additional risk factors and uncertainties that could affect the
matters discussed in the forward-looking statements. You should not
place undue reliance on forward-looking statements, which speak
only as of the date they are made, are not guarantees of future
performance or results, and are subject to risks, uncertainties and
assumptions that are difficult to predict or quantify. The Cigna
Group undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as may be required by law.
INVESTOR RELATIONS CONTACT:
Ralph Giacobbe
860-787-7968
Ralph.Giacobbe@TheCignaGroup.com
MEDIA CONTACT:
Justine Sessions
860-810-6523
Justine.Sessions@Evernorth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-cigna-group-announces-pricing-terms-of-tender-offers-302066616.html
SOURCE The Cigna Group